2. Search Result
Search Result
Results for "

renal impairment

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117985B
    Evogliptin tartrate

    DA-1229 tartrate

    		 Dipeptidyl Peptidase Autophagy Metabolic Disease Inflammation/Immunology
    Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin tartrate
  • HY-W019894
    Manganese chloride

    Manganese dichloride

    		 Biochemical Assay Reagents Apoptosis mTOR Cardiovascular Disease Neurological Disease
    Manganese chloride is an orally active MRI liver contrast agent. Manganese chloride induces Apoptosis and activates the mTOR signaling pathway. Manganese chloride induces cognitive impairment, promotes hematopoietic recovery, and reduces radiation-induced bone marrow and brain damage. It can be used for the study of renal impairment .
    Manganese chloride
  • HY-W002942
    Ferroptosis-IN-21

    1,2,3,4-Tetrahydroquinolin-8-ol; 8-hydroxy-1,2,3,4-tetrahydroquinoline

    		 Ferroptosis Reactive Oxygen Species (ROS) Inflammation/Immunology
    Ferroptosis-IN-21 is a ferroptosis inhibitor that protects against renal I/R injury by suppressing ferroptosis and directly scavenging peroxyl radicals. Ferroptosis-IN-21 displays broad-spectrum anti-ferroptotic efficacy across multiple inducers in renal tubular epithelial cells, with nanomolar potency and robust suppression of lipid Reactive Oxygen Species (ROS). Ferroptosis-IN-21 significantly ameliorates renal I/R injury in mice, reducing histological damage, functional impairment, and inflammatory cytokine expression, while decreasing lipid peroxidation biomarkers such as 4-hydroxynonenal. Ferroptosis-IN-12 can be used for research in the field of ferroptosis-targeted drug development .
    Ferroptosis-IN-21
  • HY-W250122
    Glutamic acid sodium salt

    Monosodium glutamate

    		 Biochemical Assay Reagents Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis HSP Bcl-2 Family Neurological Disease Metabolic Disease Inflammation/Immunology
    Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders .
    Glutamic acid sodium salt
  • HY-W075903
    Hexaamminecobalt(III) chloride

    Cobalt hexammine trichloride; Hexaamminecobalt trichloride

    		 Biochemical Assay Reagents SOD Glutathione S-transferase Metabolic Disease Cancer
    Hexaamminecobalt (III) chloride is an orally active cobalt coordination compound. Hexaamminecobalt (III) chloride restores the activities of liver antioxidant enzymes (SOD, Catalase) and detoxification enzyme GST. Hexaamminecobalt (III) chloride restores GSH content and reduces DAG. Hexaamminecobalt (III) chloride impairs renal function. Hexaamminecobalt (III) chloride exerts anti-carcinogenic effects in Diethylnitrosamine (HY-N7434)-induced hepatocarcinoma .
    Hexaamminecobalt(III) chloride
  • HY-W766140
    4-Hydroxy duloxetine β-D-glucuronide sodium

    4-Hydroxy duloxetine glucuronide sodium; LY550408 sodium

    		 Drug Metabolite Metabolic Disease
    4-Hydroxy duloxetine β-D-glucuronide (4-Hydroxy duloxetine glucuronide) sodium is a major metabolite of Duloxetine (HY-B0161). 4-Hydroxy duloxetine β-D-glucuronide sodium is promising for research of hepatic or renal impairment .
    4-Hydroxy duloxetine β-D-glucuronide sodium
  • HY-117985
    Evogliptin

    DA-1229

    		 Dipeptidyl Peptidase Autophagy Metabolic Disease Inflammation/Immunology
    Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin
  • HY-175247
    DDO-4033

    		E1/E2/E3 Enzyme YAP Cancer
    DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research .
    DDO-4033
  • HY-117985A
    Evogliptin hydrochloride

    DA-1229 hydrochloride

    		 Dipeptidyl Peptidase Metabolic Disease Endocrinology
    Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin hydrochloride
  • HY-117985S
    Evogliptin-d9

    DA-1229-d9

    		 Isotope-Labeled Compounds Autophagy Dipeptidyl Peptidase Metabolic Disease Inflammation/Immunology
    Evogliptin-d9 (DA-1229-d9) is deuterium labeled Evogliptin. Evogliptin (DA-1229) is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation .
    Evogliptin-d9
  • HY-110206
    AM6545

    		Cannabinoid Receptor Metabolic Disease
    AM6545 is a highly selective, brain-free (peripherally active) CB1 receptor antagonist (Ki=1.7 nM). AM6545 inhibits endocannabinoid signaling by competitively antagonizing CB1 receptors, inhibiting CB1-mediated appetite stimulation and inflammatory responses without affecting cAMP levels. AM6545 significantly reduces food intake and body weight in mice, while improving metabolic syndrome-related renal impairment (such as proteinuria, fibrosis) and insulin resistance. AM6545 can be used in the study of obesity and its complications .
    AM6545
  • HY-10965
    Rolofylline

    KW-3902

    		 Adenosine Receptor Neurological Disease
    Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
    Rolofylline
  • HY-10965R
    Rolofylline (Standard)

    		Adenosine Receptor Neurological Disease
    Rolofylline (Standard) is the analytical standard of Rolofylline. This product is intended for research and analytical applications. Rolofylline (KW-3902) is a potent, selective adenosine A1 receptor antagonist that is under development for the treatment of patients with acute congestive heart failure and renal impairment. Rolofylline is metabolized primarily to the pharmacologically active M1-trans and M1-cis metabolites by cytochrome P450 (CYP450) . Rolofylline is alleviating the presynaptic dysfunction and restores neuronal activity as well as dendritic spine levels in vitro, is an interesting candidate to combat the hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases .
    Rolofylline (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: